Our Investors Support Bold Initiatives

Jefferies 2018 Global Healthcare Conference

On Wednesday, June 6, 2018 at 8:30 a.m. Eastern Time, Michael Pehl, President and Chief Executive Officer, will present an overview of the Company at Jefferies 2018 Global Healthcare Conference.

Register Now

Immunomedics Investor Event at 2018 ASCO

On Sunday, June 3, 2018 at 7:30 p.m. Central Time, Immunomedics will host an Investor Event where updates on sacituzumab govitecan in breast and other cancers will be provided by key opinion leaders and company executives.

Register Now

Annual Report

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases.

View Annual Reports

Explore Resources for Current and Prospective Investors

Explore Resources